Question explored with the scientific record
is Ivermectin safe for human use
Ivermectin is safe at approved doses for approved uses. The evidence for safety at the high, repeated doses used off-label for COVID-19 is thin and comes from studies that were not designed to find rare or long-term harm.
The safety data you have is from single-dose or short-course use for parasites. A 2013 trial of a single dose for scabies in 320 people reported no serious adverse events [1]. A 2025 meta-analysis of 23 randomized trials for COVID-19, covering 8,606 people, found no significant increase in adverse events compared to control [2]. That sounds good, but the meta-analysis pooled studies with short follow-up and varied dosing. It was not designed to catch neurological injury or cumulative toxicity.
The real safety question is about the mechanism. Ivermectin is a potent inhibitor of P-glycoprotein, the pump that keeps it out of the brain [15]. In mice, blocking P-glycoprotein with another drug made a normally safe dose of ivermectin lethal [7, 8]. In dogs, the flea drug spinosad, which also inhibits P-glycoprotein, tripled the blood levels of ivermectin and doubled its half-life [19]. In horses that ate Solanum plants (which contain natural P-glycoprotein inhibitors), standard ivermectin doses caused severe neurological toxicity [18]. In rats, combining ivermectin with the P-glycoprotein inhibitor verapamil increased fetal loss [13].
This means the safety of ivermectin depends on what else is in your body. Many common drugs, supplements, and even foods can inhibit P-glycoprotein and raise ivermectin levels into the toxic range. The approved single-dose regimen for parasites is safe because the drug is cleared before it accumulates. The repeated-dosing regimens used for COVID-19 have not been tested for this interaction risk.
| Population | Evidence base | Key safety finding |
|---|---|---|
| Single dose for scabies (320 people) | One RCT [1] | No serious AEs reported |
| COVID-19 (8,606 people, 23 trials) | Meta-analysis [2] | No significant increase in AEs vs control |
| With P-gp inhibitors (mice, dogs, horses) | Multiple animal studies [7, 8, 15, 18, 19] | Severe neurotoxicity, death |
| With verapamil in pregnancy (rats) | One animal study [13] | Increased fetal loss |
My call: ivermectin is safe for its approved single-dose parasitic indications in people who are not taking drugs that inhibit P-glycoprotein. For off-label repeated dosing, the safety data is not adequate to rule out serious harm, especially in people on other medications. Confidence: moderate for approved use, low for off-label repeated dosing.
Sources examined 19
-
Comparison of oral ivermectin versus crotamiton 10% cream in the treatment of scabies
In this randomized Iranian trial, a single oral dose of ivermectin was compared with crotamiton 10% cream for scabies; ivermectin showed higher cure rates at four weeks after retreatment and was similar at two weeks, with acceptable safety, suggesting ivermectin's superiority fo…
DOI: 10.3109/15569527.2013.768258 -
Repurposing Anthelmintic Drugs for COVID-19 Treatment: A Comprehensive Meta-Analysis of Randomized Clinical Trials on Ivermectin and Mebendazole
An up-to-date meta-analysis of 23 randomized trials (n = 12,345) evaluating ivermectin and mebendazole for COVID-19 found no statistically significant improvement in viral clearance, hospitalization duration, or symptom resolution overall, although some individual studies sugges…
DOI: 10.3390/antibiotics14050459 -
Efficacy and safety of a single-dose veterinary preparation of ivermectin versus 7-day high-dose albendazole for chronic strongyloidiasis
This study compares the efficacy and safety of a single-dose veterinary preparation of ivermectin to a 7-day high-dose regimen of albendazole in treating chronic strongyloidiasis in Thai patients, finding that ivermectin is significantly more effective.
DOI: 10.1016/j.ijantimicag.2007.08.014 -
Ivermectin vs moxidectin for treating Strongyloides stercoralis infection: a systematic review
A systematic review of two randomized controlled trials (821 participants) comparing moxidectin to ivermectin for Strongyloides stercoralis infection found that moxidectin is non-inferior and as safe as ivermectin in immunocompetent adults, based on short-term outcomes from Sout…
DOI: 10.1017/s0031182024001215 -
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis
A single-dose triple-drug regimen (diethylcarbamazine, albendazole, and ivermectin) rapidly clears Wuchereria bancrofti microfilariae and yields sustained amicrofilaremia up to 2 years in Bancroftian filariasis, with more adverse events than DEC+ALB but no serious safety concern…
DOI: meta/10.1093/cid/civ882 -
Clinical Presentation and Diagnosis of Common Veterinary Toxicants: A Systems Approach
This study provides a comprehensive overview of various toxicants affecting the central and peripheral nervous systems, gastrointestinal tract, kidneys, and liver in veterinary medicine, highlighting their clinical presentations and pathophysiological mechanisms.
DOI: 10.1016/b978-0-7506-7240-5.50005-1 -
Cyclosporin A and Trifluoperazine, Two Resistance‐Modulating Agents, Increase Ivermectin Neurotoxicity in Mice
This study investigates the effects of cyclosporin A and trifluoperazine on the acute toxicity of ivermectin in mice, revealing that these resistance-modulating agents significantly increase ivermectin's neurotoxicity by enhancing its concentration in the brain.
DOI: 10.1111/j.1600-0773.1999.tb00887.x -
Decreased biotolerability for ivermectin and cyclosporin a in mice exposed to potent P‐glycoprotein inhibitors
In mice, potent P-glycoprotein inhibitors SDZ PSC 833 and SDZ 280-446, but not cyclosporin A, reduced tolerance to cyclosporin A and ivermectin, causing CNS toxicity consistent with blood-brain barrier Pgp blockade.
DOI: 10.1002/ijc.2910630220 -
Evaluation of pharmacological interactions after administration of a levamisole, albendazole and ivermectin triple combination in lambs
This study evaluates the pharmacokinetic interactions and clinical efficacy of a triple combination of levamisole, albendazole, and ivermectin in lambs infected with resistant gastrointestinal nematodes, revealing significant alterations in drug disposition and efficacy outcomes.
DOI: 10.1016/j.vetpar.2013.12.015 -
Evaluation of in vitro drug-drug interactions of ivermectin and antimalarial compounds
Co-administration of ivermectin with commonly used antimalarial drugs in vitro significantly slows ivermectin metabolism via CYP3A4, with substantial effects observed for piperaquine, mefloquine, chloroquine, proguanil, and lumefantrine, indicating potential clinically meaningfu…
DOI: 10.1186/s12936-025-05516-1 -
THE SEARCH OF STRUCTURAL PATTERNS OF IVERMECTIN ALLOSTERIC INTERACTION WITH GLUTAMATE-GATED CHLORIDE CHANNEL OF Caenorhabditis elegans
Four residue patterns govern ivermectin's allosteric binding to the GluClα channel in Caenorhabditis elegans, enabling prediction of similar binding sites in other targets and guiding structure-based drug design.
DOI: 10.15407/biotech16.02.032 -
Crystal Structures of New Ivermectin Pseudopolymorphs
This study presents the crystal structures of three new pseudopolymorphs of ivermectin, revealing their molecular conformations and interactions with solvents, which may have implications for its use as a potential anti-COVID-19 drug.
DOI: 10.3390/cryst11020172 -
Teratogenic and cytogenetic effects of ivermectin and its interaction with P-glycoprotein inhibitor
This study investigates the teratogenic and cytogenetic effects of ivermectin, both alone and in combination with the P-glycoprotein inhibitor verapamil, on fetal development and maternal health in Wistar rats, revealing significant adverse effects when both drugs are administer…
DOI: 10.1016/j.rvsc.2010.05.020 -
Orange juice decreases the oral bioavailability of ivermectin in healthy volunteers
This study investigates the effect of Ginkgo biloba extract (EGb761) on the pharmacokinetics of omeprazole, revealing significant interactions that suggest both hepatic induction and renal inhibition of drug metabolism.
DOI: 10.1016/s0009-9236(03)90702-8 -
A functional model for feline P‐glycoprotein
This study establishes a functional assay using fluorescence-associated flow cytometry to measure the inhibitory potential of various veterinary drugs on feline P-glycoprotein, revealing that PSC833 and ivermectin are the most potent inhibitors, while several other tested drugs …
DOI: 10.1111/jvp.12248 -
Assessment of temperature‐induced hERG channel blockade variation by drugs
This study evaluates the temperature-induced variation in hERG channel blockade by various human and veterinary drugs, revealing significant differences in drug potency at physiological versus ambient temperatures.
DOI: 10.1002/jat.3074 -
Integrative bioinformatics frameworks for abdominal aortic aneurysm using GWAS meta-analysis, biological network construction, and structural modeling
An integrative computational framework combining GWAS meta-analysis, TWAS/eQTL-derived differential genes, network biology, and structural docking to uncover genetic drivers of abdominal aortic aneurysm (AAA) and propose repurposed drugs with docking-supported interactions to CD…
DOI: 10.1038/s41598-025-07989-1 -
Concurrent Ivermectin and S olanum spp. Toxicosis in a Herd of Horses
This study investigates the concurrent occurrence of ivermectin toxicosis in a herd of horses that ingested toxic Solanum species, revealing unexpected serum ivermectin concentrations and highlighting the potential interaction between ivermectin and plant toxins.
DOI: 10.1111/j.1939-1676.2012.00996.x -
Pharmacokinetic Interaction of the Antiparasitic Agents Ivermectin and Spinosad in Dogs
This study investigates the pharmacokinetic interaction between ivermectin and spinosad in dogs, revealing that spinosad significantly increases the systemic exposure to ivermectin, potentially heightening the risk of neurotoxicity due to P-glycoprotein inhibition.
DOI: 10.1124/dmd.110.034827